[ADVERT]
Share Name Share Symbol Market Type Share ISIN Share Description
Glaxosmithkline Plc LSE:GSK London Ordinary Share GB0009252882 ORD 25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -26.00 -1.84% 1,388.00 1,386.20 1,386.40 1,414.00 1,386.00 1,411.80 7,081,426 16:35:25
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 33,754.0 6,221.0 93.9 14.8 69,831

Glaxosmithkline Share Discussion Threads

Showing 27501 to 27525 of 28675 messages
Chat Pages: Latest  1111  1110  1109  1108  1107  1106  1105  1104  1103  1102  1101  1100  Older
DateSubjectAuthorDiscuss
10/7/2021
17:09
Post ....536 Charlie9308 as in Proper Charlie.......... What evidence? Something you read in a blog from Charlie Right-old? I like to be polite but such nonsense really does try my patience.
keyno
10/7/2021
12:34
539, jeeze, I thought the waiting list was bad at my doctor's surgery! What would you eat to treat an open fracture in your leg John?
pierre oreilly
10/7/2021
09:20
let food be your medicine,let medicine be your food..hippocrates
johncasey
10/7/2021
09:19
ive not been to a doctor in 40 years,never had a pill,if i can do it why not others?
johncasey
10/7/2021
09:11
65 million people die in the UK every ninety years. Baby boomers have now reached retirement age. The market for anti-aging biotech is only going to get bigger every single year. The demand for medical services is about to explode north. Glaxo right company, right price, right everything for this time frame.
netcurtains
10/7/2021
08:55
Then the UK, one of the most highly vaccinated countries on Earth, should be full of dead bodies of the vaccinated? The evidence of your idiocy also appears to be there.
alex1621
09/7/2021
21:08
The evidence is there. JC brave post btw Keep safe all
charlie9038
09/7/2021
20:43
HTTps://www.sott.net/article/455283-Urgent-British-report-calls-for-complete-cessation-of-COVID-vaccines-in-humans?fbclid=IwAR3zN8KowmHnigkMY8X28a1Aon1CyeT74PZ02fq-1W8VAbxnvPzYdRn1pdg Urgent' British report calls for complete cessation of COVID vaccines in humans Mordechai Sones Americas Frontline Doctors Fri, 11 Jun 2021 06:53 UTC Vaccine An "urgent preliminary report of Yellow Card data" issued by the UK-based Evidence-Based Medicine Consultancy Ltd submitted to the Medicines and Healthcare Products Regulatory Agency (MHRA) states that "the MHRA now has more than enough evidence on the Yellow Card system to declare the COVID-19 vaccines unsafe for use in humans." Similar to the U.S. Vaccine Adverse Events Reporting System (VAERS), the MHRA describes the purpose of its Yellow Card system as providing "an early warning that the safety of a medicine or a medical device may require further investigation." The report, signed by Evidence-based Medicine Consultancy Ltd and EbMC Squared CiC Director Dr. Tess Lawrie (MBBCh, PhD), says: "we have searched the Yellow Card reports using pathology-specific key words to group the data according to the following five [sic] broad, clinically relevant categories: Bleeding, Clotting and Ischaemic ADRs Immune System ADRs 'Pain' ADRs Neurological ADRs ADRs involving loss of Sight, Hearing, Speech or Smell Pregnancy ADRs" The report goes on to say: "We are aware of the limitations of pharmacovigilance data and understand that information on reported Adverse Drug Reactions should not be interpreted as meaning that the medicine in question generally causes the observed effect or is unsafe to use. We are sharing this preliminary report due to the urgent need to communicate information that should lead to cessation of the vaccination rollout while a full investigation is conducted. According to the recent paper by Seneff and Nigh, potential acute and long-term pathologies include: Pathogenic priming, multisystem inflammatory disease and autoimmunity Allergic reactions and anaphylaxis Antibody dependent enhancement Activation of latent viral infections Neurodegeneration and prion diseases Emergence of novel variants of SARSCoV2 Integration of the spike protein gene into the human DNA "It is now apparent that these products in the blood stream are toxic to humans. An immediate halt to the vaccination programme is required whilst a full and independent safety analysis is undertaken to investigate the full extent of the harms, which the UK Yellow Card data suggest include thromboembolism, multisystem inflammatory disease, immune suppression, autoimmunity and anaphylaxis, as well as Antibody Dependent Enhancement (ADE)." The report concludes: "The MHRA now has more than enough evidence on the Yellow Card system to declare the COVID-19 vaccines unsafe for use in humans. Preparation should be made to scale up humanitarian efforts to assist those harmed by the COVID-19 vaccines and to anticipate and ameliorate medium to longer term effects. As the mechanism for harms from the vaccines appears to be similar to COVID-19 itself, this includes engaging with numerous international doctors and scientists with expertise in successfully treating COVID-19. "There are at least 3 urgent questions that need to be answered by the MHRA: How many people have died within 28 days of vaccination? How many people have been hospitalised within 28 days of vaccination? How many people have been disabled by the vaccination?" Comment: This is just a confirmation of the real dangers of the experimental COVID vaccines that many medical professionals were alarming about since the Covid crisis started.
johncasey
09/7/2021
20:39
Haven't looked at the detail but expect that at least one among the 72 fairer competition initiatives signed by Biden will include some element of drug pricing. Think increased downward pressure on prices is inevitable in the longer term but the industry as a whole is a powerful lobbyist so it won't be clear cut.Anyway, GSK need to get a few more things out there that patients and health systems actually want first ;)
rikky72
09/7/2021
14:49
Thanks for that additional info net. Will have a look too.
lovewinshatelosses
09/7/2021
14:26
I like m&s food. Cheaper than waitrose, and always without exception really good quality. Best value food imo, although obviously more expensive than lidl etc. So it's worth investing in is it net? May take a look.
pierre oreilly
09/7/2021
13:42
Okay thanks Sue58
abdullla
09/7/2021
13:41
lovewinshatelosses: M&S has great NAV value. It has updated its clothing range to include some pretty good brand names (Jaeger - blimy that is right). Https://www.marksandspencer.com/l/brands/jaeger/womens or white stuff: Https://www.marksandspencer.com/l/brands/white-stuff or Hobbs Https://www.marksandspencer.com/l/brands/hobbs or Sea Salt Cornwall: Https://www.marksandspencer.com/l/brands/seasalt They are at every service station and more people are going by car to work to avoid public transport. With GAP closing and no Debenhams they have the advantage of being LAST MAN STANDING takes it all. They also have good in-store tea rooms which means the old love shopping there. Its price is at a historic low-ish side. It used to be a big FTSE100 company. I can see it either recovering or being taken over. Either way I think its good as Glaxo in its own way. Cheers NEt
netcurtains
09/7/2021
13:29
Correct. 19p, 19p, 23p.
alex1621
09/7/2021
13:23
Abdullla - I think there is a dividend next February as well before the dividend decrease in May next year?
sue58
09/7/2021
13:00
jubberjim: Based on your criteria, maybe have a look at National Grid too. Not investment advice of course, etc. Interesting you like M&S as a share - I like their food range (even if it is not particularly good price value, IMO!), but as a business, especially right now, I think their best hope from a shareholder position, is a take out - which may of course be why you and your fellow holders there like it! Always thought the clothing side of the business let them down. High pension liabilities too, I presume.
lovewinshatelosses
09/7/2021
12:38
Two more divis of 19p each yet to come
abdullla
09/7/2021
12:36
jubberjim: You are a bit like me. I also like M&S.
netcurtains
09/7/2021
12:15
Have just bought in for a safe dividend paying share only 30000 grand but am quite long of cash at moment Sold all my other holdings mostly financial as going nowhere fast due to the uncertainty generally in the broader markets This and bt.a my only significant holdings but will be looking to diversify so any reputable suggestions most welcome Otherwise happy to keep long f cash until I can see more clarity God luck everyone be lucky
jubberjim
09/7/2021
09:57
Ftse up 55 points GSK now going into red rest of the markets going higher after yesterday's falls,not good.
abdullla
09/7/2021
09:49
GSK announced recently a drug that was effective after you get Covid, it never really moved the needle. It just sounds like one of many ... it's not like Viagra or an HIV cure.
alex1621
09/7/2021
09:41
I've seen the results of late-stage Clinical Trials. The vaccine has shown safety and efficacy in a late-stage trial with more than 28,000 volunteers.
tradermichael
09/7/2021
09:31
How do you know the Indian product is effective? The only pharma that comes out of India is off patent copycats, they are seldom in front of the curve on anything.
alex1621
09/7/2021
08:37
Zydus (India) about to launch a needle-free covid vaccine using novel plasmid DNA technology. GSK seem to be a long way behind the curve on researching and producing innovative vaccines in this field. The ZyCoV-D vaccine is the first ever plasmid DNA vaccine for human use and represents a key milestone in scientific innovation and technology advancement. It is delivered intradermally using the PharmaJet Tropis Needle-free Injection System, which enables enhanced vaccine effectiveness in addition to being highly preferred by patients and providers over other delivery methods. The DNA platform is ideally suited for a COVID-19 vaccine as it can be easily adapted to deal with mutations in the virus and has greater thermostability and less restrictive cold chain requirements compared with other vaccines.
tradermichael
08/7/2021
18:17
An omen for the bid price at some point (1,710.40) - 4:30pm. Nice! 08-Jul-21 16:30:25 1,423.98 360,630 Buy* 1,710.40 1,282.60 5m O
netcurtains
Chat Pages: Latest  1111  1110  1109  1108  1107  1106  1105  1104  1103  1102  1101  1100  Older
ADVFN Advertorial
Your Recent History
LSE
GSK
Glaxosmith..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210927 00:38:05